Soleno Therapeutics, Inc. (SLNO)
NASDAQ (CM) NASDAQ (CM) Primary 
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
SLNO shares surge as Neurocrine inks $2.9B cash deal to acquire it at $53 a share, adding Vykat XR and expanding its rare disease and endocrinology portfolio.
Soleno Therapeutics, Inc. $SLNO Holdings Lifted by Avoro Capital Advisors LLC
Avoro Capital Advisors LLC boosted its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO) by 25.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,577,777 shares of the company's stock after acquiring an additional 527,777 shares during the quarter. Soleno Therapeutics
Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript
Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript
Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Soleno Therapeutics (SLNO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript
Soleno Therapeutics, Inc. ( SLNO ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Anish Bhatnagar - Chairman, President, CEO & COO Meredith Manning - Chief Commercial Officer James MacKaness - CFO & Compliance Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Tyler Van Buren - TD Cowen, Research Division Moritz Reiterer - Guggenheim Securities, LLC, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd.
Soleno: Blockbuster Launch In Progress
Soleno Therapeutics is reassessed after a 24% drop post-VYKAT XR approval enthusiasm. SLNO now faces the critical 'danger zone' between FDA approval and successful commercialization of VYKAT XR for Prader-Willi syndrome. The company's hefty market cap and total reliance on VYKAT XR put it in 'show me' mode for investors.
Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Soleno Therapeutics (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Soleno Therapeutics, Inc. (SLNO) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 1:30 PM EDT Company Participants Anish Bhatnagar - Chairman, President, CEO & COO James MacKaness - CFO & Compliance Officer Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. I think we'll get started here with our next fireside discussion.
Soleno Therapeutics, Inc. (SLNO) Presents At Cantor Global Healthcare Conference 2025 Transcript
Soleno Therapeutics, Inc. (NASDAQ:SLNO ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:00 PM EDT Company Participants Anish Bhatnagar - Chairman, President, CEO & COO James MacKaness - CFO & Compliance Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Presentation Kristen Kluska Analyst Okay. Hi. Good afternoon, everybody.
Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15%
The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
